OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
Declarations
Funding The preparation
of the Adis Drug Review was not supported by any external funding.
Authorship and Conflict of interest James
Frampton is a salaried employee of Adis International Ltd/Springer Nature, and
declares no relevant conflicts of interest. All authors contributed to the
review and are responsible for the article content.
Ethics approval, Consent to participate,
Consent to publish, Availability of data and material, Code availability
not applicable
Additional information about this Adis Drug Review can be found here
Abstract
OnabotulinumtoxinA (Botox®; a formulation of botulinum toxin type A (BoNT/A)] is indicated for the prevention of headaches in adults with chronic migraine (CM) in numerous countries, including those of Europe. In clinical trials, intramuscular administration of BoNT/A (155–195 units at 12-week intervals) to patients with CM was generally well tolerated and associated with sustained and clinically meaningful improvements in multiple assessments of headache symptoms, headache-related impact and/or disability and migraine-specific health-related quality of life over a period of 1 year (in the pivotal PREEMPT 1 and 2 studies) and 2 years (in the phase IV COMPEL study). The efficacy and safety of BoNT/A therapy have been confirmed in a number of large, prospective, real-world studies conducted in Europe, including the 2-year REPOSE study. Intramuscular BoNT/A has also demonstrated greater clinical utility than the oral prophylactic medication topiramate in a clinical practice setting (FORWARD study).
Video Abstract, Script and Slides
The video abstract, script and slide deck of images from the video, which have been peer reviewed and were uploaded to Figshare after the OnabotulinumtoxinA in Chronic Migraine Adis Drug Q&A was published, are sponsored by AbbVie.
The script and slide deck can be found here.
© Springer Nature Switzerland AG 2021
